Erbitux (Cetuximab) Approved For Metastatic Head And Neck Cancer, USA

Links shared publicly online about this topic.

0
total visits

Erbitux (Cetuximab) Approved For Metastatic Head And Neck Cancer, USA

Erbitux (cetuximab) has been approved by the US FDA for combination use with chemotherapy for late-stage head and neck cancer treatment. When given together with chemotherapy, Erbitus was found to

View full resource at medicalnewstoday.com

Tags: Cancer, Chemotherapy, Head and Neck Cancer, FDA, Erbitux

Most Recently Shared on November 8, 2011 at 3:45 pm By:

Amir Abdullah Al-Bey

Erbitux (Cetuximab) Approved For Metastatic Head And Neck Cancer, USA http://t.co/xAGxR0Vj

7 months ago...

Retweet

Favorite

Also Shared By:

US FDA approval for expanded use of Erbitux | Oral Cancer News

oralcancernews.org — “US FDA approval for expanded use of Erbitux | Oral Cancer News” View full resource at oralcancernews.org

Most Recently Shared on November 9, 2011 at 8:24 am By:

The Oral Cancer Foundation Health Organization

FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News

oralcancernews.org — “FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org

Most Recently Shared on November 8, 2011 at 2:00 pm By:

The Oral Cancer Foundation Health Organization

Erbitux Approved for Metastatic Head and Neck Cancer - MPR

empr.com — “Bristol-Myers Squibb announced that Erbitux (cetuximab) has gained an expanded indication for the treatment of metastatic head and neck cancer in combination with other chemotherapy.” View full resource at empr.com

Most Recently Shared on November 7, 2011 at 8:28 pm By:

MPR Medical Publisher

Erbitux Gains Expanded Indication for Metastatic Head and Neck Cancer http://t.co/nqnyHzHm #oncology

7 months ago...

Retweet

Favorite

FDA approves Erbitux to treat late-stage head and neck cancer

fda.gov — “The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.” View full resource at fda.gov